![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Serenity Petitions FDA to Deny Ferring’s Nocturia Treatment
Serenity Petitions FDA to Deny Ferring’s Nocturia Treatment
![](https://www.fdanews.com/ext/resources/test/Drug-Images4/SerenityPharma_Logo.gif?t=1525907985&width=430)
May 9, 2018
Serenity Pharmaceuticals petitioned the FDA to deny approval of Ferring’s new drug application for a nocturia treatment, claiming the company did not demonstrate the drug’s safety or clinical benefit and did not design the drug to allow for a true safety assessment.
The company compared the product profiles of its own Noctiva (desmopressin acetate) and the new drug application, both designed to treat nocturia, a condition involving excessive nighttime urination. It claimed that there are important differences relating to dose, routes of administration, pharmacokinetic variability and excess desmopressin that make favor Noctiva a safer product.
It also pointed out differences in study methods between the two products that it claimed significantly impact Ferring’s approvability.
Upcoming Events
-
21Oct